Home › MabVax Therapeutics Receives Orphan Drug Designation For Therapeutic Vaccine To Treat Childhood Cancer Neuroblastoma
 

Keywords :   


MabVax Therapeutics Receives Orphan Drug Designation For Therapeutic Vaccine To Treat Childhood Cancer Neuroblastoma

2014-10-01 14:02:11| drugdiscoveryonline Home Page

MabVax Therapeutics Holdings, Inc. (OTCQB: TELKD), a clinical stage oncology drug development company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's vaccine intended for the treatment of the childhood cancer neuroblastoma

Tags: drug cancer treat receives

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Eastern North Pacific Tropical Weather Outlook
05.10Atlantic Tropical Weather Outlook
04.10Should you tip even if the service wasn't worth it?
04.10Hurricane Kirk Graphics
04.10Hurricane Kirk Forecast Discussion Number 22
04.10Tropical Storm Leslie Forecast Discussion Number 10
04.10Hurricane Kirk Wind Speed Probabilities Number 22
04.10Hurricane Kirk Public Advisory Number 22
More »